Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

BETHESDA, Md., April 23 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the start of a phase 1 clinical trial with its BiTE(R) antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.

MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers. Additionally, EpCAM has been found on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence of these cancers. MT110 is the second BiTE antibody in clinical trials, and the fourth clinical program in Micromet's product pipeline. The first BiTE antibody, MT103 (MEDI-538), is now in phase 1 and phase 2 clinical trials for the treatment of haematological cancers.

"BiTE antibodies enable the patients' own T cells to very efficiently eliminate tumor cells," comments Patrick Baeuerle, Chief Scientific Officer of Micromet, "In various experimental tumor models, we have demonstrated the high therapeutic potential of EpCAM-specific BiTE antibodies, and we are now looking forward to determining the safety and the therapeutic potential of MT110 in patients."

"Having obtained clinical proof of concept for our BiTE antibody technology with MT103 in haematological cancers, we are excited about exploring the potential of MT110 in treating solid tumors," comments Carsten Reinhardt, Chief Medical Officer of Micromet. "Based on its unique mode of ac
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... LOS ALTOS, Calif. , Aug. 18, 2014 ... company developing therapeutics to treat infectious diseases, has ... GBV006, for the treatment of the current Ebola ... approval for the use of GBV006, a combination ... through an established compassionate use regulatory pathway.  The ...
(Date:8/18/2014)... 2014 Reportlinker.com announces that a new ... Global Operating Room Equipment Market ... About Operating Room Equipment ... a sterile environment in a healthcare facility used ... technically advanced equipment, which ensures patient care and ...
(Date:8/18/2014)... NEW YORK , Aug. 18, 2014 /PRNewswire/ ... report is available in its catalogue: ... to 2020 http://www.reportlinker.com/p02280986/Russia-Bariatric-Surgery-Devices-Market-Outlook-to-2020.html ... to 2020 Summary ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 2Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 3Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 4Global Operating Room Equipment Market 2014-2018 2Global Operating Room Equipment Market 2014-2018 3Global Operating Room Equipment Market 2014-2018 4Global Operating Room Equipment Market 2014-2018 5Global Operating Room Equipment Market 2014-2018 6Russia Bariatric Surgery Devices Market Outlook to 2020 2Russia Bariatric Surgery Devices Market Outlook to 2020 3Russia Bariatric Surgery Devices Market Outlook to 2020 4Russia Bariatric Surgery Devices Market Outlook to 2020 5
... Nash Corporation (Nasdaq: KNSY ), today announced that it ... Euronext: DSM KON), under which DSM has agreed to acquire all ... offer, followed by a merger with a subsidiary of DSM, for ... pleased to have entered into the merger agreement with DSM, as ...
... May 2, 2012 Synteract , Inc., a ... biopharmaceutical company developing new therapies to combat the growing ... annual Great Strides fundraising walk to benefit ... Synteract and Rempex (on behalf of Aptalis Pharma) are ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sodium Chloride IV ... that one lot of Sodium Chloride IV 0.9%, USP 1000 ... to the presence of particulate matter. Sodium Chloride Injection, USP ... as a priming solution in hemodialysis procedures. , ...
(Date:8/20/2014)... At this moment, Ebola is causing horrific, ... the root cause of the virus and other problems Africans ... nonprofit organization Books For Africa to provide copies of his ... Live the Life of Their Dreams, to those who could ... with the tools they need to make the leap to ...
(Date:8/20/2014)... Over 31 million Americans suffer from low back ... pain is the single leading cause of disability worldwide, and ... Americans spend at least $50 billion each year trying to ... pain are not due to organic conditions such as arthritis; ... a busy accountant, had little time for physical activity or ...
(Date:8/19/2014)... 2014 BambooIndustry.com, a well-known bamboo product manufacturer ... deckings recently. The company is excited to reveal the ... special offer for all clients. Now, every customer can get ... will last until August 30. , The company’s deckings ... the world for supreme durability. They are perfect for a ...
(Date:8/19/2014)... What gives skin an edge and is that ... and nourish it while lightly exfoliating? The Collagen ... raves about how their skin feels and looks after using ... Beauty®. "The ingredients are very rich and spa-quality." , The ... over cleansed skin of the face and neck, and let ...
Breaking Medicine News(10 mins):Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:That "Something Special" to Improve Skin Takes Only 10 Minutes Per Week; on Sale at Sublime Beauty® 2
... combination of services plus technology helps physicians improve ... efficiency and reduce their administrative burden., ... provider of health care BPO services, today announced ... ) CBayPraxis is a revolutionary electronic patient ...
... toll on the heart, kidney and liver as well ... a high risk of early death. This sobering ... whether longevity has improved for RA patients over the ... the general population. Are earlier diagnosis, breakthrough drugs, ...
... "Kids and the Growing Allergy Threat" (p. 42). Senior ... allergies in adults,and children. Today at least 11 million ... 1997 and 2002 in children,under 5. Allergists say they,re ... not just to 1950s staples such as milk and,wheat-but ...
... Oregon Health & Science University Cancer Institute researchers ... stomachs rather than their backs is a better method ... therapies, being able to reproduce ,the positioning of the ... , It was a surprising finding, according to according ...
... ANGELES, Oct. 28 Results from a University of ... head and neck cancer can be uniformly delivered in ... cancer centers through a centralized planning and treatment process. ... meeting of the American Society for Therapeutic Radiology and ...
... La., Oct. 28 Tangiers International LLC,a global ... forces with American International Group, Inc (AIG), to ... for injured,contractors covered under the Defense Base Act. ... is excited about,this opportunity to expand with AIG, ...
Cached Medicine News:Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 2Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 3Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 4Health News:The widening mortality gap between people with rheumatoid arthritis and the general population 2Health News:The widening mortality gap between people with rheumatoid arthritis and the general population 3Health News:NEWSWEEK: Media Lead Sheet/November 5, 2007 Issue (on newsstands Monday, October 29). 2Health News:NEWSWEEK: Media Lead Sheet/November 5, 2007 Issue (on newsstands Monday, October 29). 3Health News:NEWSWEEK: Media Lead Sheet/November 5, 2007 Issue (on newsstands Monday, October 29). 4Health News:Positioning pelvic cancer patients on stomachs for radiation yields better results 2Health News:Integrated approach to IMRT provides quality care for head and neck cancer patients 2Health News:Tangiers International Announces New Medical Support Services in Iraq for American International Group (AIG) 2
... The GoodKnight 420 CPAP System is the ... (CPAP) device on the market. It is ... preserve their lifestyles while complying with therapy. ... 600 sessions of date/time usage data. It ...
Micro-hematocrit tubes available in multiple sizes and additives for a wide range of capillary blood collection....
... VH IVUS technology uses advanced spectral ... of ultrasound images and provide detailed ... patient's atherosclerotic plaques. The colorized VH ... fibrous, fibro-fatty, dense calcium, and necrotic ...
... With the GE Innova 2100IQ: See the ... legs. Place interventional devices. Its all enabled ... panel that helps deliver excellent image quality ... Innova family systems installed worldwide, more physicians ...
Medicine Products: